Skip to content
This website includes promotional information and is intended for UK healthcare professionals only. This website has been developed and funded by Exeltis UK.

Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to pharmacovigilance.uk@exeltis.com

Gepretix

This website includes Gepretix® promotional information and is intended for UK healthcare professionals only.

Micronised Progesterone: For Your Patient’s Balance in HRT

Gepretix® (micronised progesterone) 100mg & 200mg is indicated for adjunctive use with an oestrogen in post-menopausal women with
an intact uterus, as hormone replacement therapy (HRT)1,2

Gepretix® is micronised progesterone, identical in composition and action to Utrogestan 1-3

What is Gepretix®

Micronised progesterone

Gepretix® (progesterone) 100mg / 200mg soft capsules is indicated for adjunctive use with an oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT)1,2

Resources

Gepretix® Summary

Gepretix® is micronised progesterone, identical in composition and action to Utrogestan 1-3

Gepretix® 200mg is the only oral micronized progesterone in 200mg strength available in the UK market 2,4

Gepretix® is the most cost-effective brand for micronised progesterone oral capsules 5,6

Gepretix® contains bovine gelatin which is certified halal and kosher 7,8

Gepretix® is the most cost-effective brand for micronised progesterone oral capsules 5,6

Prescribe Gepretix® by brand to achieve
cost savings for the NHS vs other branded
progesterone oral capsules 5,6

Gepretix® 100 mg

£4.62

The acquisition cost of Gepretix® 100mg is £4.62 for 30 capsules. When prescribed by brand, this represents a 30% discount (£4.62 vs. £6.60) compared with the price of Utrogestan™ 5,6

Gepretix® 200 mg

£7.98

The acquisition cost of Gepretix® 200mg is £7.98 for 30 capsules. When prescribed by brand and dose, this represents a 40% discount (£7.98 vs. £13.20) compared with the price of Utrogestan™ 5,6

How to prescribe Gepretix® 1,2

01

Oestrogen replacement therapy

In women receiving oestrogen replacement therapy, there is an increased risk of endometrial cancer which can be countered by progesterone administration.1,2

02

Recommended dose

The recommended dose is 200mg daily at bedtime, for twelve days in the last half of each therapeutic cycle (beginning on Day 15 of the cycle and ending on Day 26). Withdrawal bleeding may occur in the following week.1,2

03

Alternatively

Alternatively, 100mg can be given at bedtime from Day 1 to Day 25 of each therapeutic cycle. Withdrawal bleeding is less with this treatment schedule.1,2

Contact

Request a call from a Representative

Complete the form with your information to ensure we connect you with the correct local representative.

Abbreviations: NHS, National Health Service.

References: 1. Gepretix® 100mg soft capsules Summary of Product Characteristics 2. Gepretix® 200mg soft capsules Summary of Product Characteristics 3. Utrogestan Summary of Product Characteristics 4. MIMS Hormone replacement therapy (HRT) table; Accessed July 2025 5. BNF. Available at: https://bnf.nice.org.uk/drugs/progesterone/medicinal-forms/ (Accessed March 2025)  6. Exeltis Budget Impact Model Issued March 2025 7. Centro Islamico Italiano certificate, issued August 2024 8. Certificate of Kashruth, issued 2025.

You are now leaving exeltishub.co.uk and going to an external site.

Exeltis is not responsible for websites it links to. Where our site contains links to other sites and resources provided by third parties, these links are provided for your information only.

EXE-E/IPR-CORP-2018-v2; October 2025
Cancel

This is a promotional website developed and funded by Exeltis UK and it is intended for UK healthcare professionals only.

Please confirm whether you are a UK registered healthcare professional by selecting one of the options below:
EXE-E/IPR-CORP-2018-v3, January 2026